Frank Torti joined NEA in 2007 and specializes in investments in biopharmaceuticals, medical devices, and healthcare services/IT. At NEA, Frank has partnered with entrepreneurial companies at all stages of their lifecycle and has been actively involved in both early and growth stage investments that include: Annexon Biosciences, Alimera Sciences (NASDAQ: ALIM), Cadence Pharmaceuticals (acquired by Mallinckrodt plc), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira (NASDAQ: DERM), Eargo, GST Clinics, Galera Therapeutics, Neotract (acquired by Teleflex), Novast Pharmaceuticals, OphoMed, Peplin (acquired by LEO Pharma), Rigel (NASDAQ: RIGL), Solta Medical (acquired by Valeant), and Tarveda Therapeutics
Prior to joining NEA, Frank worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Frank’s experience also includes public market investing at the Wasatch Advisors mutual fund family and business development work with the digital health startup Revolution Health Group. Frank received his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.